How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemic

I Ian C. Murphy K Kelly Bryan M Muriel Burk R Rong Jiang F Francesca Cunningham S Sarah Providence E Elizabeth Rightnour S Sarah Zavala K Kathleen Morneau T Trisha Exline S Stacey Rice T Travis Schmitt K Kelly Drumright J Jennifer Lee B BreAnna Davids T Tram Guilbeault B Brooke Klenosky A Ann-Marie Sutherland A Abbie Rosen L Lauren Ratliff K Kenneth Bukowski M Margaret A. Pisani A Andrew Franck M Mark Wong P Preston Witcher K Kathleen M. Akgün

Abstract

OBJECTIVES Early data suggested higher sedative requirements for ventilated COVID+ patients, deviating from established guidelines. We assessed the relationship between sedative use and outcomes in mechanically ventilated Veterans during the COVID-19 pandemic. Design Retrospective Medication Use Evaluation Setting National Sample of 13 Distinct VA Medical Center Intensive Care Units Patients Critically ill Veteran patients requiring mechanically ventilation for ≥2 days Interventions None. Measurements and main results The proportion of patients receiving fentanyl, midazolam and propofol was higher during COVID years. Compared with pre-COVID, median fentanyl dose was higher during Years 1 and 2 (1575mcg [(IQR) 1000–1650] vs. 1900 [1250–3000] vs. 1910 [1150–3500]). Adjuvant antipsychotics use was relatively low but tended to increase over time (pre = 10.5% vs. Year 1 = 12.3% vs. Year 2 = 14.1%). Most patients started on antipsychotics in the ICU were continued on the drug after extubation. Mortality was higher during COVID years (pre = 26.9% vs. 1 = 36.8% and 2 = 35.9%). In stratified analyses by COVID status years 1–2 (n = 79, 27%), a higher proportion of COVID+ patients received fentanyl (96% vs. 84%) and propofol (90% vs. 77%) and at higher doses (fentanyl = 1650mcg vs. 2688mcg median cumulative dose; propofol maximum infusion rate = 30 mc/kg/min (20–50) vs. 40 (25–50)). Sedative doses were similar to pre-COVID among non-COVID patients. Anti-psychotics were more frequently continued post extubation among COVID+ (34.6% vs. non-COVID+=14.9%). COVID+ patients were also less likely to have awakening and breathing trials at 48 hours after intubation (18% vs. 46%). Conclusions Sedative use and dosing increased during the first two years of COVID compared to pre-COVID, especially for COVID+ patients. The sustained elevated levels of fentanyl use in Year 2 suggests possible ‘therapeutic creep’ away from guideline-concordant practices for COVID+ patients. Antipsychotic prescription during intubation and following extubation was also more common among COVID + . These findings could inform development and implementation of safer sedation practices across VA ICUs during respiratory pandemics.

Article Details

Journal PLoS ONE
Volume / Issue Vol. 20, Issue 12
Published December 31, 2025
Pages e0340225
ISSN 1932-6203
Publisher Public Library of Science

Journal Info

PLoS ONE

Public Library of Science

ISSN: 1932-6203 Open Access Health Sciences

Authors (26)

I

Ian C. Murphy

K

Kelly Bryan

M

Muriel Burk

R

Rong Jiang

F

Francesca Cunningham

S

Sarah Providence

E

Elizabeth Rightnour

S

Sarah Zavala

K

Kathleen Morneau

T

Trisha Exline

S

Stacey Rice

T

Travis Schmitt

K

Kelly Drumright

J

Jennifer Lee

B

BreAnna Davids

T

Tram Guilbeault

B

Brooke Klenosky

A

Ann-Marie Sutherland

A

Abbie Rosen

L

Lauren Ratliff

K

Kenneth Bukowski

M

Margaret A. Pisani

A

Andrew Franck

M

Mark Wong

P

Preston Witcher

K

Kathleen M. Akgün